Intelligence Profile
Clinical Applications
Mesenchymal stem cell (MSC) therapy is being investigated across a diverse range of medical conditions, though the evidence base varies significantly by application area.
Current Clinical Trial Applications
Based on registered clinical trials, MSC therapy is being evaluated for:
Autoimmune and Inflammatory Conditions:
- Lupus nephritis (Phase 2 trial using umbilical cord-derived MSCs)
- Ankylosing spondylitis (completed molecular study)
Neurological Disorders:
- Cerebellar ataxia (completed Phase 1/2 trial)
Sexual Health:
- Erectile dysfunction in type 1 diabetes patients (Phase 1 trial using autologous intracavernous injection)
- Female sexual function impairment (Phase 2 trial using adipose tissue-derived MSCs)
Research Applications Under Investigation
Recent research has explored MSC therapy potential in several additional areas:
Cardiovascular Applications:
Human amniotic MSCs show cardioprotective properties, though specific clinical outcomes require further investigation.
Liver Regeneration:
MSC-derived hepatocytes, particularly when primed with compounds like quercetin, demonstrate enhanced liver regeneration potential in preclinical models.
Orthopedic Applications:
Both adipose-derived and dental pulp stem cells show chondrogenic (cartilage-forming) potential when grown on specialized scaffolds, suggesting applications in cartilage repair.
Ocular Disorders:
MSC-derived exosomes are being investigated for treating ocular surface disorders, representing a cell-free therapeutic approach.
Cancer-Related Side Effects:
Studies suggest MSCs may help treat methotrexate-induced mucositis, though research also indicates potential complications in certain cancer contexts.
Wound Healing:
Preconditioned MSCs show enhanced wound repair capabilities through improved angiogenic and immunoregulatory properties.
Important Limitations
The clinical evidence for MSC therapy remains limited, with many trials showing "unknown" status or being in early phases. Additionally, research has identified potential risks, including the possibility that MSCs may promote therapeutic resistance in certain cancer types, particularly EGFR-mutant non-small cell lung cancer.
Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Patients should consult with qualified healthcare providers regarding MSC therapy options and their individual medical circumstances.